Quest Diagnostics
808 hedge funds and large institutions have $12.6B invested in Quest Diagnostics in 2022 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 250 increasing their positions, 321 reducing their positions, and 82 closing their positions.
151% more call options, than puts
Call options by funds: $68.5M | Put options by funds: $27.3M
0.2% more ownership
Funds ownership: 88.32% → 88.52% (+0.2%)
5% less funds holding
Funds holding: 851 → 808 (-43)
8% less capital invested
Capital invested by funds: $13.7B → $12.6B (-$1.1B)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
22% less repeat investments, than reductions
Existing positions increased: 250 | Existing positions reduced: 321
38% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$91.3M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$79.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$74.7M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$49M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$27.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$98.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$63M |
| 3 |
APG Asset Management
Amsterdam,
Netherlands
|
-$55.9M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$48.7M |
| 5 |
Renaissance Technologies
New York
|
-$32.8M |
DGX Hedge Fund Activity: Q3 2022 in Review
808 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q3 2022, worth a combined $12.6B — down 8.1% from $13.7B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of DGX and 51 opened new positions — a net loss of 31 holders — while 321 trimmed existing stakes and 250 added.
The largest buyer was Invesco, adding an estimated $91.3M. The largest seller was BlackRock, cutting an estimated $98.1M.
- 808 institutional investors held Quest Diagnostics (DGX) as of Q3 2022, down from 851 in Q2 2022.
- Funds reported $12.6B of Quest Diagnostics stock for Q3 2022, down 8.1% quarter-over-quarter.
- 51 funds opened new Quest Diagnostics positions in Q3 2022 and 82 closed out, a net change of -31 holders.
- The largest Quest Diagnostics buyer in Q3 2022 was Invesco, an estimated $91.3M added.
- The largest Quest Diagnostics seller in Q3 2022 was BlackRock, an estimated $98.1M sold.
Based on aggregated 13F filings for Q3 2022.